Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SY-5609 |
Synonyms | |
Therapy Description |
SY-5609 selectively inhibits CDK7, potentially resulting in inhibition of tumor growth (PMID: 34726887, PMID: 32385714). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SY-5609 | SY5609|SY 5609 | CDK7 Inhibitor 16 | SY-5609 selectively inhibits CDK7, potentially resulting in inhibition of tumor growth (PMID: 34726887, PMID: 32385714). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF mutant | colorectal cancer | predicted - sensitive | SY-5609 | Preclinical - Pdx | Actionable | In a preclinical study, SY-5609 treatment resulted in 90% or more tumor growth inhibition or tumor regression in 50% (5/10) of patient-derived xenograft (PDX) models of colorectal cancer harboring BRAF mutations (J Clin Oncol 38: 2020 (suppl; abstr 3585)). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04247126 | Phase I | SY-5609 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | Completed | USA | 0 |